Late Breaking Clinical Data for Prostate Cancer Patients

Session 4: Late Breaking Clinical Data for Prostate Cancer Patients

8:05 AM – 9:20 AM

Moderators:
Howard Soule, PhD
Prostate Cancer Foundation

Introduction
Howard Soule, PhD
Prostate Cancer Foundation

Combinatorial Targeting of AR and AKT with Abiraterone and Ipatasertib for mCRPC with and without PTEN loss: The Ipatential150 Phase 3 Trial
Johann de Bono, MD, PhD
The Institute of Cancer Research; Royal Marsden Hospital, London, UK

Phase 1 Clinical Profile of AMG 160, a Half-Life Extended PSMA Bispecific T-cell Engager (BiTE®) Immunotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer
Matthew Rettig, MD
University of California, Los Angeles; VA Greater Los Angeles Healthcare System

Phase 1 Study of AMG 509, a STEAP1 x CD3 T Cell–Recruiting XmAb® 2+1 Immune Therapy, in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Wm. Kevin Kelly, DO
Sidney Kimmel Medical College at Thomas Jefferson University; Sidney Kimmel Cancer Center

Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy: Focus in Prostate Cancer
Dimitris Skokos, PhD
Regeneron Pharmaceuticals

Elizabeth Miller, MD
Regeneron Pharmaceuticals

Live Session Discussion

9:20 AM – 9:25 AM     Please Return to the Virtual Lobby to Join the Next Session

82 cents of every dollar donated goes to our prostate cancer research mission

Join the fight against prostate cancer today. Donate